StemCell Therapy

Investment to the tune of US$25m has been announced by Hendrix Genetics in the form of a new commercial turkey hatchery in South Dakota, United States.

The hatchery will provide up to 30m day-old Hybrid poults and lead to the addition of 100 new temporary and permanent jobs at the site at Beresford.

The new hatchery will have the capacity for 35m hatching eggs and will be fitted with cutting edge equipment to ensure the highest biosecurity and poult quality.

Dave Libertini, Hendrix Genetics managing director, said: The new hatchery allows us to continue to deliver on our core focus of providing top quality genetics that match the needs of the market and our customers. Photo: ANP / Justin Sullivan

It is part of a substantial investment plan by Hendrix, which includes new hatcheries, egg production facilities and a modern transportation fleet and follows previous investments in grandparent facilities in Kansas and Nebraska.

Dave Libertini, Hendrix Genetics managing director, said: The new hatchery allows us to continue to deliver on our core focus of providing top quality genetics that match the needs of the market and our customers. This is a critical component of our plan to modernise the commercial turkey distribution infrastructure in the USA.

Matt McCready, Hendrix Genetics director of business development, added the hatchery would join the network of owned, aligned and contracted hatchery capacity set up to supply the strong demand for Hybrid genetics in the USA.

To comment, login here Or register to be able to comment.

Go here to see the original:
Hendrix Genetics announce new US turkey hatchery investment - Poultry World (subscription)

This entry was posted on July 12, 2017 at 5:01 pm and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |